Skip to content
Parakho

Eris Lifesciences Ltd

NSE ERISBSE 540596eris.co.in

Q1 FY27, unaudited

Revenue
₹443.99 Cr
Profit after tax
₹48.30 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations443.99−23.27%1,821.74
Other income26.38+16.31%98.31
Total income470.37−21.78%1,920.05
Employee benefit expense90.84−3.13%340.62
Finance costs42.16−6.60%179.54
Depreciation & amortisation39.98+6.33%154.38
Total expenses406.23−8.72%1,543.33
Profit before tax64.14−58.95%362.05
Tax expense15.84−71.85%118.00
Profit after tax48.30−51.70%244.05
Total comprehensive income48.42−51.33%244.74
Earnings per share
Earnings per share, basic₹3.49₹17.86
Earnings per share, diluted₹3.48₹17.83

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

A transcript for the Q1 FY27 call was filed with the exchange; Parakho has not summarised it yet.

All quarters

Filings

12 shown · 56 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 07 Oct 2026.